Compare Dow Jones Industrial Average ETF (DIA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Dow Jones Industrial Average ETF trades at $515.77 (market cap $45.20B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: Dow Jones Industrial Average ETF is far larger — about 4.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 4,095,368). Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DIA | XBI | |
|---|---|---|
Market Cap | $45.20B | $10.11B |
Volume | 4,095,368 | 12,903,266 |
52-Week High | $542.79 | $169.55 |
52-Week Low | $451.37 | $104.99 |
Typical Hold Time | 103 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $515.82, up 0.94% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 46.24, while recent dividend distributions provide income appeal. Support levels cluster around $507-510 with resistance at $513-516.
Market sentiment reflects cautious optimism amid economic uncertainty, with institutional focus on Fed policy and earnings resilience. Key risks include interest rate sensitivity and market volatility, though the ETF's diversified Dow Jones exposure offers defensive characteristics in turbulent markets.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
